Abstract A novel dimeric gadolinium(III) complex, bis(4-Gd-DTPA-aminophenyl)adamantane (5), was successfully synthesized using bis(4-aminophenyl)adamantane to link two Gd-DTPA units. All the intermediates and bis(4-Gd-DTPA-aminophenyl)adamantane (5) have been characterized by 1H NMR,… Click to show full abstract
Abstract A novel dimeric gadolinium(III) complex, bis(4-Gd-DTPA-aminophenyl)adamantane (5), was successfully synthesized using bis(4-aminophenyl)adamantane to link two Gd-DTPA units. All the intermediates and bis(4-Gd-DTPA-aminophenyl)adamantane (5) have been characterized by 1H NMR, 13C NMR, ES-API-MS, HR-ESI-MS, FT-IR and elemental analysis (EA). The longitudinal relaxivity of bis(4-Gd-DTPA-aminophenyl)adamantane is 8.43 mM−1 Gd−1 s−1 at 0.43 T (32 °C, pH 7.0), and 4.89 mM−1 Gd−1 s−1 at 3.0 T (32 °C, pH 7.4). The T1-weighted imaging in vitro showed that bis(4-Gd-DTPA-acetylaminophenyl)adamantane can enhance the contrast of images distinctly. But most of all, the kinetic inertness of bis(4-Gd-DTPA-aminophenyl)adamantane (5) was comparable to that of [Gd(DTPA)(H2O)]2− (Magnetvist®). Moreover, cytotoxicity tests indicated that the bis(4-Gd-DTPA-acetylaminophenyl)adamantane exhibited low toxicity to healthy liver cells (L-02 cells). These results demonstrate that the Gd(III) complex 5 may be a promising MRI contrast agent candidate.
               
Click one of the above tabs to view related content.